MannKind highlights Furoscix ReadyFlow evidence at HFSA 2026
MannKind (MNKD) shared data at HFSA 2026 supporting Furoscix ReadyFlow™ for outpatient management of edema in heart failure (HF) and chronic kidney disease (CKD).
MannKind (MNKD) shared data at HFSA 2026 supporting Furoscix ReadyFlow™ for outpatient management of edema in heart failure (HF) and chronic kidney disease (CKD).